Recent developments underscore innovation in rare diseases and artificial intelligence, reshaping treatment paradigms and accelerating drug development.
Recent developments underscore innovation in rare diseases and artificial intelligence, reshaping treatment paradigms and accelerating drug development.
March 2025 is marked by significant deal-making, promising clinical trial results, and innovations across small molecules, biologics, and …
India’s Sun Pharmaceutical Industries strengthens its immuno-oncology capabilities with acquisition of U.S.-based Checkpoint Therapeutics.
The biopharma sector sees soaring merger and acquisition activity in March 2025, with major deals advancing innovation in …
Long-term data demonstrate that EBGLYSS offers durable skin improvement and symptom relief, reinforcing its role as a first-line …
Partnerships harnessing artificial intelligence are revolutionizing drug discovery, reducing timelines and improving candidate success rates.
Investments in next-generation manufacturing facilities are unlocking scale, speed, and quality for cell and gene therapies, propelling North …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
Record venture investment is driving new biotech companies in Australia to accelerate research, clinical development, and global partnerships.
